12:43 uur 01-09-2016

PXT3003 van Pharnext in vier posterpresentaties op zesde internationale conferentie Charcot-Marie-Tooth and Related neuropathy Consortium (CMTR)

PARIJS–(BUSINESS WIRE)–Pharnext, een Franse biofarmaceutisch bedrijf dat een geavanceerd portfolio van producten tegen neurodegeneratieve aandoeningen, heeft vandaag bekendgemaakt dat onderzoeksresultaten in verband met zijn centrale pleomedicijn PXT3003 worden gepresenteerd op de zesde internationale conferentie van het  Charcot-Marie-Tooth and Related neuropathy Consortium (CMTR). Het gaat om vier posterpresentaties over het medicijn, dat in ontwikkeling is als voor de behandeling van de ziekte Charcot-Marie-Tooth type 1A. De conferentie vindt van 8 tot 10 september 2016 plaats in Venetië.

De vier posters worden gepresenteerd in twee aparte postersessies:

Postersessie #2 – Vrijdag 9 september, 2016 – 13:30 tot 14:30 uur.

Poster 20: “International, multi-center, randomized, double-blind, placebo-controlled Phase 3 study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth disease type 1A treated for 15 months.” Attarian S, et al.

Poster 21: “Baseline Analysis of PXT3003 Phase 2 Data Reveals Two Blood Early Candidate Biomarkers for Therapeutic Response in Charcot-Marie-Tooth Disease Type 1A.” Laffaire J, et al.

Postersessie #3– Zaterdag 10 september, 2016 – 12:30 tot 13:30 uur.

Poster 18: “An Online Survey of Neurologists about Charcot-Marie-Tooth Disease Type 1A.” Paoli X, et al.

Poster 29: “An Experimental Trial of an Early Onset Short-Term Treatment with a Combinational Drug (PXT3003) in the Charcot-Marie-Tooth 1A Rat Model.” Prukop T, et al.

 

 

Pharnext’s PXT3003 Featured in Multiple Presentations at the 6th International Charcot-Marie-Tooth and Related Neuropathy Consortium (CMTR) Meeting

 

PARIS–(BUSINESS WIRE)– Regulatory news:

Pharnext (Paris:ALPHA) (ISIN FR00111911287), a French biopharmaceutical company developing an advanced portfolio of products in the field of neurodegenerative diseases, today announced that data related to its lead pleodrug PXT3003, being developed for the treatment of Charcot-Marie-Tooth type 1A disease (CMT1A), will be presented in four posters at the 6 thinternational Charcot-Marie-Tooth and Related neuropathy Consortium (CMTR) conference in Venice on September 8-10, 2016.

These four posters will be presented at two distinct poster sessions during the conference:

  • Poster Session #2 – Friday September 9 th , 2016 – 1:30 to 2:30pm
  • Poster 20: “International, multi-center, randomized, double-blind, placebo-controlled Phase 3 study assessing in parallel groups the efficacy and safety of 2 doses of PXT3003 in patients with Charcot-Marie-Tooth disease type 1A treated for 15 months.” Attarian S, et al.
  • Poster 21: “Baseline Analysis of PXT3003 Phase 2 Data Reveals Two Blood Early Candidate Biomarkers for Therapeutic Response in Charcot-Marie-Tooth Disease Type 1A.” Laffaire J, et al.
  • Poster Session #3 – Saturday September 10 th , 2016 – 12:30 to 1:30pm
  • Poster 18: “An Online Survey of Neurologists about Charcot-Marie-Tooth Disease Type 1A.” Paoli X, et al.
  • Poster 29: “An Experimental Trial of an Early Onset Short-Term Treatment with a Combinational Drug (PXT3003) in the Charcot-Marie-Tooth 1A Rat Model.” Prukop T, et al.

About Pharnext
c is an advanced clinical stage biopharmaceutical company founded by renowned scientists and entrepreneurs including Professor Daniel Cohen, a pioneer in modern genomics. Pharnext focuses on neurodegenerative diseases and has two lead products in clinical development: PXT3003 is currently in an international Phase 3 trial for the treatment of Charcot-Marie-Tooth disease type 1A and benefits from orphan drug status in Europe and the United States. PXT864 has generated positive Phase 2 results in Alzheimer’s disease. Pharnext is the pioneer of a new drug discovery paradigm: pleotherapy. The Company identifies and develops synergic combinations of repositioned drugs at low dose. These “pleodrugs” offer several key advantages: efficacy, safety, and intellectual property including several composition of matter patents already granted. The Company is supported by a world-class scientific team.

The company Pharnext is listed on Euronext Alternext Stock Exchange in Paris (ISIN code: FR00111911287).

For more information, please visit www.pharnext.com

Contacts

Pharnext
René Goedkoop, +33 (0)1 41 09 22 30
M.D.
Chief Medical Officer
medical@pharnext.com
or
NewCap
Investors Relations
Julie Coulot, +33 (0)1 44 71 20 40
pharnext@newcap.eu
or
Media Relations (Europe)
Alize RP
Caroline Carmagnol
Margaux Pronost
+33 (0)1 44 54 36 64
pharnext@alizerp.com
or
Media Relations (US)
Russo Partners
Tony Russo, Ph.D.
Matt Middleman, M.D.
+1 212-845-4251
+1 212-845-4272
tony.russo@russopartnersllc.com
matt.middleman@russopartnersllc.com
Check out our twitter: @NewsNovumpr